Greenwich LifeSciences

Update in progress

GLSI (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on cancer immunotherapies for HER2/neu-expressing cancers, including breast cancer, in the United States and Romania. Its lead candidate, GP2, is in Phase III to prevent breast cancer recurrence after surgery. FLAMINGO-01 is a Phase III trial evaluating GLSI-100 (GP2 + GM-CSF) in HER2-positive breast cancer. Formerly Norwell, Inc., renamed Greenwich LifeSciences in 2018. Founded 2006, based in Stafford, Texas.

Company score

Sentiment: 0.50; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive